| HOME >> BIOLOGY >> TECHNOLOGY |
EAST NORRITON, Pa., Dec. 13, 2011 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced that new data from the Company's Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) programs are featured in several presentations at the TERMIS North America Annual Conference being held December 11-14, in Houston, TX.
The NUC program is further supported by various cellular and molecular studies demonstrating the genetic stability of the autologous smooth muscle cells used in the Neo-Urinary Conduit. Supporting the utility of the technology platform are additional experiments showing the suitability of using adipose-derived smooth muscle cells from bladder cancer patients who have undergone prior cancer treatment. In support of advancing the NKA program toward clinical studies, Tengion has previous demonstrated increased survival in an obese, diabetic rat model of chronic kidney disease. A new analysis using multiple species, including canines, demonstrated that NKA had broad regenerative outcomes in multiple kidney tissue compartments. Renal filtration, tubular and urine concentrating effects were all shown to be improved and constitute significant predictors for survival. To support clinical translation, prototype formulations which combined selected regenerative renal cells with various gelatin-based hydrogels were well-tolerated and elicited neo-kidney tissue regeneration.
"These presentations highlight the work of Tengion scientists to translate regenerative medicine science into product candidates for patients," said Tim Bertram, DVM, Ph.D., President, Research and Development and Chief Scientific Officer of Tengion. "In our two lead programs, we continue to build the evidence for the specific cells and biomaterials used in our product candidates and their potential to address impo
'/>"/>
| SOURCE Tengion, Inc. Copyright©2010 PR Newswire. All rights reserved |